Understanding China’s Access Environment for Orphan Therapies: Advancing Policies and Diagnosis & Treatment Capacities
In our previous installment, we delved into the distinctive characteristics and commercial challenges surrounding rare diseases, highlighting a comprehensive solution
Understanding China’s Access Environment for Orphan Therapies: 3 Key Considerations
Biopharmaceutical companies face distinctive challenges when it comes to developing and commercializing treatments for rare diseases, as these conditions affect
Access Pathway for Innovative Medicines in China: Pure Commercial Health Insurance
In the last installment, we introduced City Commercial Health Insurance (City CHI), a type of all-inclusive commercial health insurance positioned
Access Pathway for Innovative Medicines in China: City Commercial Health Insurance ("Huiminbao")
In the first installment of this 3-part China access pathway series, we discussed the basic social medical insurance (BMI)/the
Access Pathway for Innovative Medicines in China: Basic Social Medical Insurance
To understand the access pathways for innovative medicines in China, we have to follow the money.
Three layers in China’
